Enabling Pro-Resolving Lipid Mediator Therapeutics

Once thought to be a passive event, the resolution of inflammation is now known to be a highly regulated, active process that depends on a class of molecules known as specialized pro-resolving mediators (SPMs). SPMs are endogenous inflammatory mediators derived from n-3 and n-6 polyunsaturated fatty acids (PUFAs) that act on immune cells to induce apoptosis, inhibit the expression of pro-inflammatory cytokines, and initiate the clearance of cellular debris. SPMs include E-series resolvins derived from eicosapentaenoic acid, protectins, maresins, and D-series resolvins derived from docosahexaenoic acid, and lipoxins derived from arachidonic acid.

The SPMs represent a new class of pharmacologically active agents that occur endogenously but have not yet been developed into prescription drugs due to lack of intellectual property protection as natural entities. Using our HEALER platform technology to create small molecule derivatives of SPMs, we are developing innovative drug products that deliver the natural lipid mediators with composition of matter patent protection, thus avoiding the need for synthetic analogs. This enables efficient development of first-in-class agents for treatment of inflammatory diseases with low risk of off-target effects.

Use of the n-3 and n-6 PUFAs in the prescription drug arena also has been limited by several factors including low bioavailability, poor stability, lack of intellectual property protection, and physico-chemical characteristics that are unsuitable for conventional oral and parenteral dosage forms. Application of HEALER is an efficient way to overcome these deficits to create new medicines with properties that enable new therapeutic indications with long-term, patent-protected commercial viability.

Learn more about our HEALER platform. »»